Publications
Peptide Receptor Radionuclide Therapy With
177Lu-DOTATATE for Patients With Somatostatin Receptor-Expressing Neuroendocrine Tumors
64Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor–Positive Neuroendocrine Tumors: Results of the First U.S. Prospective, Reader-Masked
Clinical Trial
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
Preclinical Investigation of 212Pb-DOTAMTATE for Peptide Receptor Radionuclide Therapy in a Neuroendocrine Tumor Model
